Andrew Berens

Aydin Huseynov

Biren Amin

Joseph Pantginis

Michael Schmidt

Sean McCutcheon

Robert Driscoll

Steven Willey

Amin Makarem

Maury Raycroft

Tully on for Steven Willey

- Compass Therapeutics' lead drug, Tivesamig, a DLL4 VEGF A bispecific antibody, is on track for **overall survival and progression-free survival endpoint readouts in Q1 2026** for advanced biliary tract cancer, with the company planning to seek **full regulatory approval**.  **[1738021_tx_379752_0]** **[1738021_tx_379752_1]** 
- The estimated fully penetrated market opportunity for Tivesamig in second-line biliary tract cancer in the United States alone is **greater than $3 billion annually**, and the company is preparing for self-commercialization in the U.S..  **[1738021_tx_379752_3]** 
- The company also has two other bispecific antibodies in development: 8371 (PD-one PD-L1) showing **deep responses in Phase I** for non-small cell lung cancer and triple-negative breast cancer, and 726 (PD-one VEGF A) with an **IND submission planned for late 2025**.  **[1738021_tx_379752_0]** 
- Compass Therapeutics reported pro forma **$230 million in cash** at the end of Q2 2025, providing a cash runway well into **2028**.  **[1738021_tx_379752_6]**

Compass Therapeutics Discusses Tivesamig Clinical Progress and Commercial Strategy

Compass Therapeutics (CMPX)